KLOWDosage & Reconstitution Calculator

A 4-peptide skincare cocktail in a single vial — fixed 50/10/10/10 mass ratio at 80 mg total. KPV is the layer that distinguishes it from GLOW. KLOW is also sometimes labeled "KLOW-80" or "KLOW 80mg" — same product. Not for weight loss; none of the four peptides act on appetite or fat signaling.

Four peptides at fixed mass ratios:

Total: 80 mg. The 50/10/10/10 ratio puts most of the vial mass into GHK-Cu because collagen rebuilding is the continuous daily demand the protocol is built around.

"Blend" and "stack" both refer to the same single-vial 4-peptide composition: GHK-Cu + BPC-157 + TB-4 + KPV in the fixed 50/10/10/10 ratio. "Blend" emphasizes the premixed format (one vial, one reconstitution); "stack" is the broader peptide-community term for compounds used together. For KLOW, the two terms point to the same product.

KLOW's value is structural skin work paired with active inflammation control — the combination matters more than any single peptide:

• Collagen rebuilding and matrix quality — GHK-Cu turns on collagen production at the gene level and clears damaged tissue in parallel.
• Capillary supply to the repair area — BPC-157 sprouts new small blood vessels so the rebuilding has nutrient delivery.
• Repair-cell migration and anti-scarring — TB-4 (full-length, 43 aa) moves repair cells into position and biases healing toward functional tissue rather than rope-like scarring.
• Inflammation control — KPV pre-empts the inflammation switch (NF-κB) before it activates, so reactive skin doesn't drown the rebuilding signals.

Visible timeline: subtle texture change weeks 1–2, tone evening weeks 3–4, fine lines softening by 4–6, structural firmness and scar remodeling by 8–12. KLOW is not for weight loss, acute injury (TB-4 underdoses at the cocktail's per-dose level — see Injury Anchor section above), or as a topical (subcutaneous injection only).

Skincare anchor: subtle texture change weeks 1–2; visible tone evening weeks 3–4; collagen-quality changes weeks 5–6; full cycle effect weeks 7–8.

Injury anchor: inflammation reduction by week 2; functional improvements weeks 4–6; structural progress through weeks 8–12.

If past week 6 with no noticeable change: verify the certificate of analysis (CoA), check injection technique and storage, and for injury protocols confirm the full-length TB-4 bolus is in place (see the Injury Anchor section). Baseline week-0 photos are the cleanest tracking method for skincare progress.

Yes. Fibroblast remodeling and inflammation resolution both consume your cellular energy and redox floor. Chronic skin reactivity and tissue repair carry a high oxidative cost, and GHK-Cu's architectural work is energy-expensive. Adding NAD+ supports the metabolic floor underneath sustained remodeling, making it especially relevant if you are fatigued, slow to rebound, or running a caloric deficit (such as on a GLP-1).

Rule: Different syringe, different site. NAD+ is acidic (pH ~4) and will destabilize the peptide solution if co-injected. Schedule them at least 30 minutes apart, or on different days entirely. NAD+ stings more than KLOW; a slow injection and room-temperature solution help.

Yes. GLP-1s (semaglutide, tirzepatide, retatrutide) and KLOW operate on completely separate receptor systems, so there is no pharmacological interference. Pairing them is common during active weight-loss phases to provide skin and tissue support against the laxity and slowed recovery that rapid caloric deficits can cause.

Start with the anchor that matches your goal:

• 2 mg GHK-Cu daily for skincare (reconstitute the vial with 2.5 mL BAC water)
• 0.5 mg BPC-157 daily for injury recovery (reconstitute the vial with 2 mL of BAC water)

By using those BAC water ratios for an 80mg vial of KLOW, your daily dose becomes an easy-to-remember 10-unit U-100 syringe draw.

New users often benefit from a lower first-week dose to assess tolerance — halve the anchor (1 mg GHK-Cu or 0.25 mg BPC-157) for week 1, then step to the full anchor dose from week 2 onward.

Use the KLOW Calculator tool to automatically calculate your preferred starting dose.

KLOW is designed around daily subcutaneous dosing before reducing to a maintenance level of 2-5x / week. GHK-Cu and KPV work well at daily intervals, and BPC-157's nanogram-threshold mechanism also supports daily. To dive deeper, read our GLOW / KLOW anti-aging protocol.

Injury-focused users sometimes move to three injections per week at higher per-dose volumes to better accommodate TB-4's bolus-driven mechanism — but this reduces the single-injection convenience that makes KLOW a practical alternative to four separately-dosed peptides. If the anchor trade-offs don't fit the injury, a non-blend stack like the Injury Recovery Protocol is the cleaner path.

The cleaner fix for injury use is daily KLOW plus 2×-weekly standalone TB-500 (3-5mg 2-3x/week at the injury site). Daily rhythm stays; TB-4 saturation happens on its own schedule via the standalone.

Standard cycling is 6–8 weeks on, 2–4 weeks off for skincare, and 8–12 weeks on, 2–4 weeks off for injury recovery. Cycling preserves the distinction between active protocol and maintenance and gives a clean reference point for evaluating whether the approach is working.

Pick an anchor based on the goal:

• Skincare: 2 mg GHK-Cu daily, subcutaneous. Reconstitute the 80 mg vial with 2.5 mL BAC water; draw 0.1 mL (10 units on a U-100 insulin syringe) for each dose.
• Injury: 0.5 mg BPC-157 daily, subcutaneous near the injury site. Reconstitute with 2 mL BAC water; same 0.1 mL draw.

The other peptides come along at fixed proportions. Cycle 8–12 weeks active, then 4–8 weeks off (or step down to 2–3× weekly maintenance). Use the KLOW Dosage Calculator above to solve any custom anchor dose or vial size.

One 0.1 mL injection per day (10 units on a U-100 syringe) at 2.5 mL reconstitution for skincare or 2 mL reconstitution for injury anchoring. That delivers either 2 mg GHK-Cu + 0.4 mg each of BPC-157, TB-4, and KPV (skincare anchor) or 2.5 mg GHK-Cu + 0.5 mg each of BPC-157, TB-4, and KPV (injury anchor). Don't double up missed doses — GHK-Cu's effect runs on cumulative tissue exposure, so daily consistency matters more than dose magnitude.

Daily during the activation phase (weeks 1–4), tapering to 5×/week during weeks 5–8, then 2–3× weekly for maintenance from week 9 onward. Same per-injection volume across phases — only the frequency changes. Pulsed maintenance keeps the repair signal present without blunting the response over long cycles.

8–12 weeks active, then 4–8 weeks off — or transition to 2–3× weekly maintenance instead of a hard break. Indefinite daily dosing isn't the default. Some operators run quarterly 4-week intensive cycles every 3–4 months instead of continuous maintenance.

For any target anchor dose D (mg) and anchor mass M in the vial (GHK-Cu = 50 mg, BPC-157 = 10 mg):

$$V_{\text{water}}=\frac{V_{\text{draw}}\times M}{D}$$

Worked example — 3.5 mg GHK-Cu, 20-unit (0.2 mL) draw:

$$V_{\text{water}}=\frac{0.2\text{ mL}\times 50\text{ mg}}{3.5\text{ mg}}=2.86\text{ mL BAC water}$$

The KLOW Calculator above solves this for any anchor and draw volume.

Add bacteriostatic water (BAC water) directly to the lyophilized 80 mg vial. Standard volumes:

• 2.5 mL for the skincare anchor (2 mg GHK-Cu per 0.1 mL draw)
• 2 mL for the injury anchor (0.5 mg BPC-157 per 0.1 mL draw)
• 5 mL if you prefer a 0.2 mL (20-unit) draw — easier syringe-mark reading and reduced concentration-dependent sting

Tilt the vial and let the water flow down the inside wall (don't spray directly at the lyophilized cake — disrupts the structure). Swirl gently to dissolve; don't shake. The reconstituted solution should turn clear blue from the GHK-Cu copper content. A colorless solution suggests missing or under-dosed GHK-Cu. See the Reconstitution Guide for the full step-by-step.

For an 80mg vial of KLOW, the recommended bacteriostatic (BAC) water volume depends on your primary goal:

• For Skincare (2 mg GHK-Cu anchor): Add 2.5 mL of BAC water. This provides 25 daily doses of 10 units (0.1 mL). Each dose delivers: - 2 mg GHK-Cu - 0.4 mg BPC-157 - 0.4 mg TB-4 - 0.4 mg KPV

• For Injury Repair (0.5 mg BPC-157 anchor): Add 2 mL of BAC water. This provides 20 daily doses of 10 units (0.1 mL). Each dose delivers: - 2.5 mg GHK-Cu - 0.5 mg BPC-157 - 0.5 mg TB-4 - 0.5 mg KPV

Using 2 to 3 mL is the standard range. Higher volumes (like 4 or 5 mL) can be used to dilute the solution further if the injection stings, though it will require injecting a larger liquid volume per dose.

At this anchor dose, your per-injection payload will be:

• 3.5 mg GHK-Cu
• 0.7 mg BPC-157
• 0.7 mg TB-4
• 0.7 mg KPV

Easiest clean draw (2.85 mL BAC water → 17.5 mg GHK-Cu/mL): 0.2 mL (20 units on a U-100 syringe) delivers the 3.5 mg GHK-Cu target. By adding a precise 2.85 mL of BAC water, your daily injection lands exactly on the 20-unit mark. Vial lasts 14 daily doses.

Lower injection volume (1.43 mL BAC water → 35 mg GHK-Cu/mL): 0.1 mL (10 units) per dose. Smaller volume but tighter syringe read; also a more concentrated sting on injection.

Larger draw for 5mL vials (4.28 mL BAC water → 11.6 mg GHK-Cu/mL): 0.3 mL (30 units) per dose. More volume to inject, but forces a clean 30-unit read, and dilution meaningfully reduces the GHK-Cu sting.

At this anchor dose, your per-injection payload will be:

• 1.75 mg GHK-Cu
• 0.35 mg BPC-157
• 0.35 mg TB-4
• 0.35 mg KPV

Easiest clean draw (2.85 mL BAC water → 3.5 mg BPC-157/mL): 0.1 mL (10 units) delivers the 0.35 mg BPC-157 target. Adding exactly 2.85 mL BAC water forces a perfect 10-unit draw. Vial lasts 28 daily doses.

Lower injection volume (1.43 mL BAC water → 7 mg BPC-157/mL): 0.05 mL (5 units) per dose. Tighter read, smallest volume, more concentrated GHK-Cu at the injection site.

Larger draw for 5mL vials (4.28 mL BAC water → 2.3 mg BPC-157/mL): 0.15 mL (15 units) per dose. Cleaner syringe read; dilution also helps the GHK-Cu sting at this anchor's higher GHK-Cu payload.

Subcutaneously in any rotated site for the skincare anchor — abdomen, thigh, or lateral hip work. Rotate sites to avoid local irritation. For the injury anchor, inject near the injury site when practical: first-pass tissue concentration is higher near the injection site before systemic dilution⁷, which matters disproportionately for TB-4's concentration-dependent mechanism. See Where to Inject Peptides for the full anatomical breakdown.

Refrigerate at 2–8°C (36–46°F). Keep away from direct light. Do not freeze. Use within 28 days of reconstitution. Discard if the solution becomes cloudy, loses its blue tint, or develops particulate.

Most common: a 30–60 second sting from the copper-peptide complex in GHK-Cu — fades within a minute. Less common: mild fatigue 12–24h post-dose (TB-4-driven), local injection-site redness, occasional brief flushing. The blue color in the vial is normal — that's the copper.

To reduce the sting: add more BAC water (lower concentration), warm the vial 10 minutes before drawing, inject slowly (5-second push), rotate sites.

Hard contraindications: active malignancy, Wilson's disease or copper-handling disorders, pregnancy, WADA-tested competition (TB-4 is on the prohibited list), surgery within the past 2 weeks.

Skip it; don't double up. A single missed daily injection has minimal protocol impact — GHK-Cu's effect runs on cumulative tissue exposure, not on any single dose. If you miss 3+ consecutive doses during weeks 1–2, restart the activation timeline.

KLOW is GLOW plus a fourth peptide, KPV. The shared three peptides — GHK-Cu, BPC-157, full-length TB-4 — sit at identical masses in both blends, so dosing math doesn't change between them. KPV pre-empts the inflammation switch (NF-κB) that drives reactive flushing, post-procedure redness, and rosacea-pattern inflammation. The 50/10/10/10 ratio in KLOW is the 50/10/10 GLOW ratio with KPV layered on top.

Calm skin → GLOW. Reactive, post-procedure, or inflammation-driven → KLOW.

Standard heuristic: start with GLOW; switch to KLOW if inflammation limits your results.

Yes. The shared three peptides are at identical masses, so the per-injection dose math doesn't change — only the per-dose payload picks up an extra 0.4–0.5 mg KPV when you switch from GLOW to KLOW (or drops it going the other way). Some practitioners run KLOW during active inflammatory flares (rosacea, post-procedure, reactive periods) and GLOW during stable periods.

Yes, with one caveat: TB-4 lands at 0.5 mg per dose at the BPC-157 anchor — that's background tissue-organization signaling, not the higher concentration injury work needs. BPC-157 and KPV are in-range at the 0.5 mg anchor; TB-4 isn't. Raising KLOW's dose to saturate TB-4 would overdose GHK-Cu.

The fix: daily KLOW + a full-length TB-4 bolus at 2–4 mg, 2–3× weekly, injected near the injury site. TB-500 (the 17–23 fragment) is an acceptable substitute when full-length isn't available — labels blur the two routinely⁷, so verify what's in the vial. The Ac-SDKP anti-fibrotic action⁴ runs through full-length, not the fragment. See the Injury Anchor section above for the full protocol.